FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

Department of Nuclear Medicine and PET Research, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
European Journal of Nuclear Medicine (Impact Factor: 5.22). 11/2009; 37(1):181-200. DOI: 10.1007/s00259-009-1297-4
Source: PubMed

ABSTRACT The aim of this guideline is to provide a minimum standard for the acquisition and interpretation of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG). This guideline will therefore address general information about[18F]-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) and is provided to help the physician and physicist to assist to carrying out,interpret, and document quantitative FDG PET/CT examinations,but will concentrate on the optimisation of diagnostic quality and quantitative information.

Download full-text


Available from: Thomas Beyer, Jun 27, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Several studies have been conducted concerning the radiation dose to hospital personnel from positron emission tomography (PET) radiopharmaceuticals, but to date only one parallel study has been conducted for veterinary staff. Veterinary patients present challenges not encountered with human patients, as they require anesthesia and therefore more intensive monitoring than human patients. This paper presents a simple model for estimating the effective radiation dose to veterinary staff using occupational dose data from PET studies at Colorado State University's (CSU) James L. Voss Veterinary Teaching Hospital. The model consists of three point sources within a soft tissue cylinder, and sample calculations are provided for estimating dose to nuclear medicine technologists and an anesthesia technologist based on four different sized dogs. The estimated doses are within the range of actual occupational doses published previously. There are different protocols for the sequence of events in veterinary PET, specifically the order of anesthesia induction and radiopharmaceutical injection. When F-FDG injection is performed prior to anesthesia induction, the estimated dose is between 1.5 and 3.6 times higher than the doses received if injection is done after anesthesia induction, although expected doses for both protocols are below occupational dose limits based on a case load of 100 veterinary patients per year. The model is based on the techniques used at CSU, but it can be modified for different hospitals as well as differently sized animals.
    Health physics 05/2014; 106(5):583-91. DOI:10.1097/HP.0000000000000037 · 0.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer represents an increasingly frequent cancer diagnosis worldwide. An increasing awareness on smoking cessation as an important mean to reduce lung cancer incidence and mortality, an increasing number of therapy options and a steady focus on early diagnosis and adequate staging have resulted in a modestly improved survival. For early diagnosis and precise staging, imaging, especially positron emission tomography combined with CT (PET/CT), plays an important role. Other functional imaging modalities such as dynamic contrast-enhanced CT (DCE-CT) and diffusion-weighted MR imaging (DW-MRI) have demonstrated promising results within this field. The purpose of this review is to provide the reader with a brief and balanced introduction to these three functional imaging modalities and their current or potential application in the care of patients with lung cancer.
    Clinical Physiology and Functional Imaging 12/2013; 34(5). DOI:10.1111/cpf.12104 · 1.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:Cell-free DNA (cfDNA) circulating in the blood holds a possible prognostic value in malignant diseases. Under malignant conditions, the level of cfDNA increases but the biological mechanism remains to be fully understood. We aimed to examine the correlation between cfDNA and total tumour burden defined by positron emission tomography (PET) parameters.Methods:Patients with advanced non-small cell lung cancer (NSCLC) were enrolled into a prospective biomarker trial. Before treatment, plasma was extracted and the level of cfDNA was determined by qPCR. An (18)F-fluorodeoxyglucose ((18)F-FDG) PET/computed tomography (CT) scan was performed and evaluated in terms of metabolic tumour volume (MTV) and total lesion glycolysis (TLG). Tumour contours were delineated semi-automatically by a threshold standardised uptake value (SUV) of 2.5. The primary end point was correlation among cfDNA, MTV and TLG. The secondary end point was overall survival (OS) according to cfDNA, MTV and TLG.Results:Fifty-three patients were included. There were no correlations between cfDNA and MTV (r=0.1) or TLG (r=0.1). cfDNA >75th percentile was correlated with shorter OS (P=0.02), confirmed in a multivariate analysis. MTV>the median was associated with a significantly shorter OS (P=0.02). There was no significant difference in OS according to TLG (P=0.08).Conclusion:Cell-free DNA may not be a simple measure of tumour burden, but seems to reflect more complex mechanisms of tumour biology, making it attractive as an independent prognostic marker.British Journal of Cancer advance online publication 14 November 2013; doi:10.1038/bjc.2013.705
    British Journal of Cancer 11/2013; 110(2). DOI:10.1038/bjc.2013.705 · 4.82 Impact Factor